Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ampyra, Patents, And The Perils Of Letting PTAB Get Your Hopes Up

Executive Summary

In an unusual twist, district court ruled Acorda patents invalid after company defeated Kyle Bass' inter partes review challenge; Bass has won 10 IPR decisions, lost 9 and has one pending.

Advertisement

Related Content

Keeping Track: US FDA Refuses To File Acorda, SteadyMed NDAs
Acorda Enacts 'Poison Pill' In Effort To Stave Off Scopia
ANDA Case Filings Drop 32%, But Still High Compared To Last Decade
Alkermes Brushes Off IP Pressures To Look to Potential Blockbuster Vivitrol
Acorda Defeats Kyle Bass, Now Awaits Ruling In Ampyra ANDA Litigation
New Patent Battleground: Inter Partes Reviews Besiege Innovators
Patent Challenges Via IPR Still Pretty Scary, Even After Acorda's Win

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120368

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel